Abstract
Background and Objectives: To establish the feasibility of sentinel lymph node (SLN) identification in patients with stage IB1 invasive cervical cancer. Methods: Selected patients with cervical cancer scheduled for radical hysterectomy with bilateral pelvic lymphadenectomy underwent SLN detection. Preoperatively, 1 mCi of technetium-99 (99Tc) was injected into four points of the superficial cervical stroma around the tumor. Intraoperatively, the patients underwent gamma-probe-guided lymphatic mapping, and patent blue dye was injected into the same points as the 99Tc. Results: Of the 12 eligible patients, 11 (92%) had at least one SLN detected. Seven (64%) patients had SLNs detected by intraoperative lymphoscintigraphy and the blue-dye technique, 3 (27%) by intraoperative lymphoscintigraphy, and 1 (9%) by the blue-dye technique only. Intraoperatively, 22 SLNs were detected: 9 (41%) by lymphoscintigraphy, 7 (32%) by lymphoscintigraphy and the blue-dye technique, and 6 (27%) by the blue-dye technique only. Six patients (54.5%) had bilateral SLNs. Sensitivity, specificity, positive predictive value, and negative predictive value for SLN detection were 100%, 80%, 33%, and 100%, respectively. There were no false-negative results. Conclusions: In this small cohort of patients, the combination of 99Tc and patent blue dye was safe and feasible for the detection of SLNs in early-stage cervical cancer. This study investigates the sentinel lymph node technique in patients with stage IB1 cervical cancer.
Keywords: Sentinel lymph node (SLN), cervical cancer, patent blue dye, technetium
Current Cancer Therapy Reviews
Title: Sentinel Lymph Node Identification in Patients with Stage IB1 Invasive Cervical Carcinoma
Volume: 3 Issue: 3
Author(s): Ricardo dos Reis, Eduardo Belmonte Tavares, Beatriz Amaral, Heleusa Ione Monego, Marcia Binda, Valentino Magno, Waldemar Rivoire, Maria Isabel Edelweiss and Edison Capp
Affiliation:
Keywords: Sentinel lymph node (SLN), cervical cancer, patent blue dye, technetium
Abstract: Background and Objectives: To establish the feasibility of sentinel lymph node (SLN) identification in patients with stage IB1 invasive cervical cancer. Methods: Selected patients with cervical cancer scheduled for radical hysterectomy with bilateral pelvic lymphadenectomy underwent SLN detection. Preoperatively, 1 mCi of technetium-99 (99Tc) was injected into four points of the superficial cervical stroma around the tumor. Intraoperatively, the patients underwent gamma-probe-guided lymphatic mapping, and patent blue dye was injected into the same points as the 99Tc. Results: Of the 12 eligible patients, 11 (92%) had at least one SLN detected. Seven (64%) patients had SLNs detected by intraoperative lymphoscintigraphy and the blue-dye technique, 3 (27%) by intraoperative lymphoscintigraphy, and 1 (9%) by the blue-dye technique only. Intraoperatively, 22 SLNs were detected: 9 (41%) by lymphoscintigraphy, 7 (32%) by lymphoscintigraphy and the blue-dye technique, and 6 (27%) by the blue-dye technique only. Six patients (54.5%) had bilateral SLNs. Sensitivity, specificity, positive predictive value, and negative predictive value for SLN detection were 100%, 80%, 33%, and 100%, respectively. There were no false-negative results. Conclusions: In this small cohort of patients, the combination of 99Tc and patent blue dye was safe and feasible for the detection of SLNs in early-stage cervical cancer. This study investigates the sentinel lymph node technique in patients with stage IB1 cervical cancer.
Export Options
About this article
Cite this article as:
Ricardo dos Reis , Eduardo Belmonte Tavares , Beatriz Amaral , Heleusa Ione Monego , Marcia Binda , Valentino Magno , Waldemar Rivoire , Maria Isabel Edelweiss and Edison Capp , Sentinel Lymph Node Identification in Patients with Stage IB1 Invasive Cervical Carcinoma, Current Cancer Therapy Reviews 2007; 3 (3) . https://dx.doi.org/10.2174/157339407781368332
DOI https://dx.doi.org/10.2174/157339407781368332 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Treatment with Radix Euphorbiae Ebracteolatae Significantly Decreases the Expression of E6 and L1, and Increases the Expression of p53 and Rb in HPV18-infected Human Foreskin Keratinocytes
Current Molecular Medicine Synthesis of 2-substituted Furo[3,2-b]pyridines Under Pd/C-Cu Catalysis Assisted by Ultrasound: Their Evaluation as Potential Cytotoxic Agents
Anti-Cancer Agents in Medicinal Chemistry Nanomedicine as a Strategy for Natural Compound Delivery to Prevent and Treat Cancers
Current Pharmaceutical Design Aldose Reductase: A Multi-disease Target
Current Enzyme Inhibition Disulfiram's Anticancer Activity: Evidence and Mechanisms
Anti-Cancer Agents in Medicinal Chemistry A General Method for the Synthesis of 3,3-bis(indol-3-yl)indolin-2-ones, bis(indol-3-yl)(aryl)methanes and tris(indol-3-yl)methanes Using Naturally Occurring Mandelic Acid as an Efficient Organo-catalyst in Aqueous Ethanol at Room Temperature
Current Green Chemistry Metallic Colloid Nanotechnology, Applications in Diagnosis and Therapeutics
Current Pharmaceutical Design Opportunities and Challenges for Host-Directed Therapies in Tuberculosis
Current Pharmaceutical Design Toll-Like Receptors: Cost or Benefit for Cancer?
Current Pharmaceutical Design siRNA Therapy, Challenges and Underlying Perspectives of Dendrimer as Delivery Vector
Current Pharmaceutical Design Current Perspective of Natural Alkaloid Carbazole and its Derivatives as Antitumor Agents
Anti-Cancer Agents in Medicinal Chemistry Bioinformatic Analysis Reveals Key Genes and Pathways in Aging Brain of Senescence-accelerated Mouse P8 (SAMP8)
CNS & Neurological Disorders - Drug Targets Role of Poly(ADP-ribose) Polymerase (PARP1) in Viral Infection and its Implication in SARS-CoV-2 Pathogenesis
Current Drug Targets Advances of Metal Enhanced Fluorescence Applications for the Biomedical Field
Current Proteomics Recent Advances and Approaches in Targeting Apoptosis Signaling Pathways for Anti-Cancer Therapeutics
Current Cancer Therapy Reviews The Discovery of HPV and its Clinical Implications
Current Cancer Therapy Reviews Chemoprotective Mechanism of the Natural Compounds, Epigallocatechin- 3-O-Gallate, Quercetin and Curcumin Against Cancer and Cardiovascular Diseases
Current Medicinal Chemistry Preface
Current Proteomics The Paths to Neurodegeneration in Genetic Parkinson's Disease
CNS & Neurological Disorders - Drug Targets High Mobility Group Box-1 (HMGB1): A Potential Target in Therapeutics
Current Drug Targets